Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression.
The antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer.
An antibody-drug conjugate given concurrently with stereotactic radiotherapy to treat brain metastases may increase patients risk for symptomatic radiation necrosis, a study suggests.
Datopotamab deruxtecan led to better progression-free survival and safety compared with standard chemotherapy in patients with metastatic HER-2 negative breast cancer.
Understanding the toxicities associated with antibody-drug conjugates could help oncologists develop strategies to diminish adverse events that arise during treatment with these powerful agents